Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Participants completed primary vaccination series (3 doses) with VLA15 Primary vaccination series to be followed by a booster a...
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical tria...
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA159,437* participants en...
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has ...
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, announces today it will present on the mosquito-borne chikung...
Saint-Herblain (France), February 16, 2023 – Valneva SE (NASDAQ:VALN, PARIS:VLA) a specialty vaccine company, today reported it...
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it completed enrollment and vaccination ...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced today the pricing of 21,000,000 ordinary shares in a global offering t...
Valneva SE (NASDAQ:VALN, PARIS:VLA) (the "Company"), a specialty vaccine company, today announced its intention to issu...
